[go: up one dir, main page]

NO20013641L - BAFF, relaterte blokkeringsmidler samt anvendelse derav ved stimulering og inhibering av B-celler og immunoglobuliner iimmunresponser - Google Patents

BAFF, relaterte blokkeringsmidler samt anvendelse derav ved stimulering og inhibering av B-celler og immunoglobuliner iimmunresponser

Info

Publication number
NO20013641L
NO20013641L NO20013641A NO20013641A NO20013641L NO 20013641 L NO20013641 L NO 20013641L NO 20013641 A NO20013641 A NO 20013641A NO 20013641 A NO20013641 A NO 20013641A NO 20013641 L NO20013641 L NO 20013641L
Authority
NO
Norway
Prior art keywords
baff
immunoglobulins
stimulating
inhibiting
cells
Prior art date
Application number
NO20013641A
Other languages
English (en)
Other versions
NO20013641D0 (no
Inventor
Jeffrey Browning
Christine Ambrose
Fabienne Mackay
Jurg Tschopp
Pascal Schneider
Original Assignee
Apotech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26815006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20013641(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apotech Sa filed Critical Apotech Sa
Publication of NO20013641D0 publication Critical patent/NO20013641D0/no
Publication of NO20013641L publication Critical patent/NO20013641L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Oppfinnelsen tilveiebringer fremgangsmåter for å behandle eller forebygge forstyrrelser assosiert med ekspresjon av BAFF, innbefattende BAFF og fragmenter derav, antistoffer, agonister og antagonister.
NO20013641A 1999-01-25 2001-07-24 BAFF, relaterte blokkeringsmidler samt anvendelse derav ved stimulering og inhibering av B-celler og immunoglobuliner iimmunresponser NO20013641L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11716999P 1999-01-25 1999-01-25
US14322899P 1999-07-09 1999-07-09
PCT/US2000/001788 WO2000043032A2 (en) 1999-01-25 2000-01-25 Baff, inhibitors thereof and their use in the modulation of b-cell response

Publications (2)

Publication Number Publication Date
NO20013641D0 NO20013641D0 (no) 2001-07-24
NO20013641L true NO20013641L (no) 2001-09-25

Family

ID=26815006

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20013641A NO20013641L (no) 1999-01-25 2001-07-24 BAFF, relaterte blokkeringsmidler samt anvendelse derav ved stimulering og inhibering av B-celler og immunoglobuliner iimmunresponser
NO20120524A NO20120524A1 (no) 1999-01-25 2012-04-27 Anvendelse av BAFF-relaterte antistoff for fremstilling av medikamenter mot lymfoproliferative sykdommer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20120524A NO20120524A1 (no) 1999-01-25 2012-04-27 Anvendelse av BAFF-relaterte antistoff for fremstilling av medikamenter mot lymfoproliferative sykdommer

Country Status (29)

Country Link
US (1) US6869605B2 (no)
EP (5) EP2298332B1 (no)
JP (5) JP5066314B2 (no)
KR (1) KR100834809B1 (no)
CN (1) CN100340292C (no)
AT (2) ATE247482T1 (no)
AU (1) AU762839B2 (no)
BR (1) BR0007719A (no)
CA (1) CA2360062A1 (no)
CY (2) CY1107453T1 (no)
CZ (1) CZ299819B6 (no)
DE (1) DE60004635T2 (no)
DK (2) DK1415659T3 (no)
EA (1) EA006108B1 (no)
EE (1) EE05699B1 (no)
ES (1) ES2204528T3 (no)
HK (1) HK1040628B (no)
HU (1) HUP0105283A3 (no)
IL (3) IL144202A0 (no)
IS (1) IS5993A (no)
MX (1) MXPA01007464A (no)
NO (2) NO20013641L (no)
NZ (1) NZ513284A (no)
PL (1) PL198934B1 (no)
PT (2) PT1146892E (no)
SI (1) SI1146892T1 (no)
SK (1) SK286665B6 (no)
TR (2) TR200102147T2 (no)
WO (1) WO2000043032A2 (no)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175208A1 (en) * 1996-10-25 2003-09-18 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
EP0878552A1 (en) 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molecular detection of chromosome aberrations
AU3516899A (en) 1998-05-04 1999-11-23 Dako A/S Method and probes for the detection of chromosome aberrations
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
EP2298332B1 (en) 1999-01-25 2015-07-08 Biogen MA Inc. BAFF, inhibitors thereof and their use in the modulation of the B-cell response
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
WO2000068378A1 (en) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
KR100897082B1 (ko) 1999-08-17 2009-05-14 바이오겐 아이덱 엠에이 인코포레이티드 Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU2048501A (en) * 2000-02-16 2001-08-27 Genentech Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
KR20120053525A (ko) 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002016412A2 (en) * 2000-08-18 2002-02-28 Dyax Corp. Binding polypeptides for b lymphocyte stimulator protein (blys)
US20030091565A1 (en) * 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EA010435B1 (ru) 2001-05-11 2008-08-29 Амген, Инк. Связывающиеся с tall-1 молекулы и их применение
DK1436003T3 (da) 2001-05-24 2010-03-15 Zymogenetics Inc TACI-immunoglobulin-fusionsproteiner
IL160127A0 (en) * 2001-08-03 2004-06-20 Genentech Inc Tacis and br3 polypeptides and uses thereof
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
WO2003035846A2 (en) 2001-10-24 2003-05-01 National Jewish Medical And Research Center Structure of tall-1 and its cognate receptor
WO2003072713A2 (en) * 2002-02-21 2003-09-04 Biogen Idec Ma Inc. Use of bcma as an immunoregulatory agent
CA2492447A1 (en) * 2002-07-25 2004-02-05 Genentech, Inc. Taci antibodies and uses thereof
WO2004039841A2 (en) 2002-10-29 2004-05-13 Borean Pharma A/S Trimeric binding proteins for trimeric cytokines
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2004074511A1 (en) * 2003-02-21 2004-09-02 Garvan Institute Of Medical Research Diagnosis and treatment of baff-mediated autoimmune diseases and cancer
AU2004220078A1 (en) * 2003-03-07 2004-09-23 Xencor, Inc BAFF mutants with at least one amino acid substitution and methods of their production
AU2004233164B2 (en) 2003-03-28 2009-10-08 Biogen Ma Inc. Truncated BAFF receptors
PT2272868E (pt) * 2003-06-05 2015-07-07 Genentech Inc Terapêutica de combinação para distúrbios de células b
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
CN1897966A (zh) 2003-10-20 2007-01-17 比奥根艾迪克Ma公司 使用baff拮抗剂的治疗方法
JP2008505607A (ja) 2004-01-29 2008-02-28 ジェネンテック・インコーポレーテッド Ｂｃｍａの細胞外ドメインの変異体とその使用法
JP5570681B2 (ja) * 2004-08-31 2014-08-13 興和株式会社 抗ヒトｂａｆｆ抗体
CA2583900A1 (en) 2004-10-13 2006-04-27 The Washington University Use of baff to treat sepsis
US20080254030A1 (en) * 2005-01-28 2008-10-16 Charles Mackay Use of Baff to Treat Th2-Mediated Conditions
EP1844069A4 (en) * 2005-01-28 2009-05-20 Apollo Life Sciences Ltd MOLECULES AND CHIMESE MOLECULES THEREOF
KR20080025066A (ko) * 2005-05-18 2008-03-19 바이오겐 아이덱 인크. 섬유성 상태의 치료 방법
AR059025A1 (es) 2005-08-09 2008-03-12 Zymogenetics Inc Metodos para el tratamiento y prevencion de proliferacion de celulas anormales utilizando moleculas de fusion taci
US7842292B2 (en) 2005-08-09 2010-11-30 Ares Trading S.A. Methods for treating B-cell malignancies using a TACI-Ig fusion molecule
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR20080074120A (ko) * 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
UA98462C2 (ru) 2006-05-15 2012-05-25 Арес Трейдинг С.А. Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
EP2396035A4 (en) * 2009-02-12 2012-09-12 Human Genome Sciences Inc USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
KR101717809B1 (ko) * 2010-03-11 2017-03-17 질레드 코네티컷 인코포레이티드 이미다조피리딘 ｓｙｋ 억제제
WO2013171296A1 (en) 2012-05-16 2013-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic and treatment of sarcoidosis
CZ304104B6 (cs) * 2012-08-22 2013-10-23 Masarykova Univerzita B-bunecný aktivující faktor pro zvýsení sliznicní imunity kojencu a prípravek jej obsahující
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
US9688767B2 (en) 2013-03-15 2017-06-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of predicting survival time in myocardial infarction patients by measuring BAFF levels
KR101493592B1 (ko) 2013-04-29 2015-02-17 부산대학교 산학협력단 Ｓｏｃｓ3 단백질을 이용한 ｂａｆｆ 연관 면역질환 치료제 스크리닝 방법
MY183188A (en) 2013-11-19 2021-02-18 Regeneron Pharma Non-human animals having a humanized b-cell activating factor gene
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
US9840543B2 (en) 2014-01-31 2017-12-12 Boehringer Ingelheim International Gmbh Anti-BAFF antibodies
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
US12023367B2 (en) 2015-06-19 2024-07-02 University Of Louisville Research Foundation, Inc. Immunomodulation for the long term prevention and treatment of autoimmune diseases and foreign tissue rejection
CN107328620B (zh) * 2017-06-23 2020-06-05 浙江普罗亭健康科技有限公司 用于流式细胞技术的封闭缓冲液及试剂盒
WO2019126366A2 (en) * 2017-12-19 2019-06-27 The Johns Hopkins University Baff therapy to promote anti- tumor immunity
US20210238295A1 (en) * 2018-04-26 2021-08-05 University Of Virginia Patent Foundation Compositions and methods for treating abdominal aortic aneurysm
JP2022521413A (ja) 2019-02-22 2022-04-07 クロノス バイオ インコーポレイテッド Ｓｙｋ阻害剤としての縮合ピラジンの固体形態

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6541224B2 (en) * 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
JP2001501453A (ja) 1996-03-14 2001-02-06 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒト腫瘍壊死因子δおよびε
EP0939804B2 (en) * 1996-10-25 2011-06-15 Human Genome Sciences, Inc. NEUTROKINE alpha
SE9603950L (sv) 1996-10-29 1997-10-27 Bjoern Hellstroem Klämskyddslist
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
EP1012292A1 (en) * 1997-06-06 2000-06-28 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
JP2002517977A (ja) 1997-06-06 2002-06-18 リジェネロン ファーマシューティカルズ，インコーポレイテッド Ｔｎｆリガンドファミリーのｎｔｎ−２メンバー
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
TR200000654T2 (tr) 1997-09-12 2000-07-21 Apotech R & D Sa KAY-Yeni bir bağışıklık sistemi proteini.
WO1999012965A2 (en) 1997-09-12 1999-03-18 Biogen, Inc. April- a novel protein with growth effects
CA2310987A1 (en) 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU1467000A (en) 1998-11-04 2000-05-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
AU780805B2 (en) 1999-01-07 2005-04-21 Ares Trading S.A. Soluble receptor BR43x2 and methods of using
EP2298332B1 (en) * 1999-01-25 2015-07-08 Biogen MA Inc. BAFF, inhibitors thereof and their use in the modulation of the B-cell response
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
EP1860190A3 (en) 1999-02-23 2008-03-12 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variants
WO2000050633A1 (en) 1999-02-24 2000-08-31 The General Hospital Corporation Method for cloning signal transduction intermediates
WO2000068378A1 (en) 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
WO2001058949A2 (en) * 2000-02-11 2001-08-16 Biogen, Inc. Heterologous polypeptide of the tnf family
KR20120053525A (ko) 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
WO2002018620A2 (en) 2000-08-15 2002-03-07 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
CA2467521A1 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys

Also Published As

Publication number Publication date
KR100834809B1 (ko) 2008-06-05
PL349772A1 (en) 2002-09-09
CN100340292C (zh) 2007-10-03
DK1146892T3 (da) 2003-11-24
SK10442001A3 (sk) 2002-02-05
EP2298332A1 (en) 2011-03-23
HUP0105283A2 (hu) 2002-04-29
KR20010105331A (ko) 2001-11-28
HK1040628A1 (en) 2002-06-21
CZ20012696A3 (cs) 2001-10-17
NZ513284A (en) 2003-10-31
DE60004635T2 (de) 2004-06-09
JP2014141527A (ja) 2014-08-07
ATE515267T1 (de) 2011-07-15
US20020037852A1 (en) 2002-03-28
PL198934B1 (pl) 2008-08-29
EP2319527A3 (en) 2011-10-12
IL144202A (en) 2010-04-29
BR0007719A (pt) 2001-11-13
JP2009102326A (ja) 2009-05-14
HK1065724A1 (en) 2005-03-04
EP1146892A2 (en) 2001-10-24
JP2012126749A (ja) 2012-07-05
NO20013641D0 (no) 2001-07-24
HUP0105283A3 (en) 2004-08-30
EP1415659A1 (en) 2004-05-06
ES2204528T3 (es) 2004-05-01
EP1415659B9 (en) 2012-02-15
MXPA01007464A (es) 2003-06-06
IL200498A0 (en) 2011-07-31
JP4955642B2 (ja) 2012-06-20
EP2298332B1 (en) 2015-07-08
EP1146892B1 (en) 2003-08-20
TR200403498T2 (tr) 2005-03-21
HK1040628B (en) 2005-10-14
IL144202A0 (en) 2002-05-23
EA200100822A1 (ru) 2002-02-28
US6869605B2 (en) 2005-03-22
SI1146892T1 (en) 2004-02-29
CY1112458T1 (el) 2015-12-09
WO2000043032A3 (en) 2000-12-14
EP1415659B1 (en) 2011-07-06
EE200100386A (et) 2002-12-16
DK1415659T3 (da) 2011-10-03
WO2000043032A2 (en) 2000-07-27
EP2974736A1 (en) 2016-01-20
PT1146892E (pt) 2003-12-31
SK286665B6 (sk) 2009-03-05
CN1347326A (zh) 2002-05-01
TR200102147T2 (tr) 2002-04-22
CZ299819B6 (cs) 2008-12-03
AU3214200A (en) 2000-08-07
IS5993A (is) 2001-07-06
AU762839B2 (en) 2003-07-03
EA006108B1 (ru) 2005-08-25
EE05699B1 (et) 2014-02-17
PT1415659E (pt) 2011-10-13
ATE247482T1 (de) 2003-09-15
NO20120524A1 (no) 2012-04-27
CY1107453T1 (el) 2012-05-23
JP2002535285A (ja) 2002-10-22
EP2319527A2 (en) 2011-05-11
JP2012087145A (ja) 2012-05-10
JP5066314B2 (ja) 2012-11-07
CA2360062A1 (en) 2000-07-27
DE60004635D1 (de) 2003-09-25

Similar Documents

Publication Publication Date Title
NO20013641L (no) BAFF, relaterte blokkeringsmidler samt anvendelse derav ved stimulering og inhibering av B-celler og immunoglobuliner iimmunresponser
AU2002366641A1 (en) Methods for inhibiting ocular processes
BG108214A (en) Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
IL172646A0 (en) Antibodies against interleukin -22 and uses therefor
BR9814040A (pt) Agudo no pulmão com fibrose com antagonistas de avb6
WO2000029574A3 (en) Inflammation-associated genes
EA200400235A1 (ru) Комбинированная терапия для лечения рака
WO2000018922A8 (en) Human carbohydrate-associated proteins
WO2000012703A3 (en) Protein transport-associated molecules
WO1999049038A3 (en) Human calcium-binding proteins
WO2000078953A3 (en) Human transport proteins
WO2000000594A3 (en) Human transferases
WO2001007471A3 (en) Cell cycle and proliferation proteins
WO2001044448A3 (en) Human oxidoreductase proteins
WO1999041373A3 (en) Human transport-associated molecules
WO1999038981A3 (en) Human protein kinase molecules
DE69534753D1 (de) Nierenpolycystose-gen
WO2003063688A3 (en) Protein modification and maintenance molecules
WO2000065054A3 (en) Human membrane-associated proteins
TR200100240T2 (tr) Anksiyete bozukluklarının tedavisi
WO2000003015A3 (en) Human transport protein homologs
WO2000008155A3 (en) Human receptor-associated proteins
WO2000060082A3 (en) Vesicle associated proteins
WO1999038976A3 (en) Human growth factor homologs
WO2000024911A3 (en) Human phospholipases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application